COPD Exacerbation — Adult Management

Key Points

• Consider pneumonia, heart failure, pulmonary embolism, pneumothorax, and ACS rather than labeling every dyspneic COPD patient an exacerbation.
• Titrate oxygen, commonly to 88% to 92% initially in patients at risk for CO2 retention.
• Use a short-acting beta agonist with or without ipratropium for rapid bronchodilation.
• A 5-day systemic corticosteroid course is sufficient for most exacerbations.
• Give antibiotics for sputum-purulent bacterial presentations or when mechanical ventilation is required, not routinely for all exacerbations.
• Use NIV early for appropriate acute hypercapnic respiratory failure with acidosis.
• Failure of NIV or inability to protect the airway requires timely intubation rather than prolonged ineffective noninvasive support.
• Discharge care should address maintenance inhalers and prevention, not only completion of acute medications.

Algorithm

1. Assess oxygenation, work of breathing, mental status, hemodynamics, and alternative diagnoses.
2. Titrate supplemental oxygen and obtain blood gas testing when respiratory failure or hypercapnia is possible.
3. Give repeated inhaled short-acting beta agonist and add short-acting antimuscarinic therapy.
4. Start systemic corticosteroid therapy unless contraindicated.
5. Add antibiotics when sputum purulence with increased symptoms or ventilatory support indicates likely benefit.
6. Start NIV for appropriate acute hypercapnic respiratory acidosis and reassess gas exchange and work of breathing quickly.
7. Intubate when NIV fails, is contraindicated, or the patient deteriorates.
8. Before discharge, optimize long-acting therapy, technique, smoking cessation, vaccination, and follow-up.

Clinical Synopsis & Reasoning

The 2026 GOLD framework defines exacerbations clinically while emphasizing that pneumonia, heart failure, pulmonary embolism, pneumothorax, myocardial ischemia, arrhythmia, and other conditions can mimic or accompany COPD worsening. Ask about baseline oxygen use, prior exacerbations, intubations, inhaler adherence, sputum change, fever, chest pain, edema, and thromboembolic risk. Severity is judged by respiratory effort, gas exchange, mental status, hemodynamics, and comorbidity rather than wheezing intensity alone.

Provide oxygen when hypoxemic and titrate rather than giving unrestricted high-flow oxygen to every patient. A target saturation of about 88% to 92% is commonly used in patients at risk for hypercapnic respiratory failure until blood gas information is available. Hypercapnia itself does not mean oxygen should be withheld; the objective is adequate oxygenation without excessive hyperoxia while ventilation is supported.

Obtain blood gas testing in severe exacerbations, altered mental status, suspected hypercapnia, or need for ventilatory support. Chest radiography is appropriate when pneumonia, edema, pneumothorax, or other acute cardiopulmonary disease is possible. Viral testing, ECG, troponin, BNP, D-dimer or CT angiography are selected according to the differential rather than ordered routinely in every exacerbation.

Treatment Strategy & Disposition

Use inhaled short-acting beta-2 agonists, with or without a short-acting antimuscarinic, as initial bronchodilator therapy. Metered-dose inhaler with spacer and nebulization are both effective when delivered correctly. Systemic corticosteroids shorten recovery and reduce treatment failure; GOLD commonly recommends prednisone-equivalent 40 mg daily for 5 days in adults, using oral therapy when absorption is reliable.

Antibiotics are indicated when bacterial infection is likely, particularly with increased sputum purulence plus increased dyspnea or sputum volume, or when invasive or noninvasive mechanical ventilation is required. Regimen choice depends on local resistance, recent antibiotic exposure, severity, and risk for Pseudomonas. A 5-day course is often adequate for improving uncomplicated exacerbations. Avoid routine antibiotics when bacterial features are absent.

Noninvasive positive-pressure ventilation is first-line ventilatory support for many patients with acute hypercapnic respiratory failure and respiratory acidosis who can protect the airway and cooperate. It reduces intubation and mortality. Intubate when there is inability to protect the airway, refractory hypoxemia, hemodynamic instability, worsening acidosis despite NIV, severe agitation, or another contraindication. Before discharge, optimize maintenance inhalers, smoking cessation, vaccination, pulmonary rehabilitation referral, and an exacerbation action plan.

Epidemiology / Risk Factors

• COPD exacerbations are a major cause of hospitalization and are associated with accelerated decline and future exacerbation risk.
• Respiratory viral infection, bacterial infection, air pollution, and medication nonadherence are common triggers.
• Frequent prior exacerbations strongly predict future events.
• Smoking is the dominant modifiable risk factor in many patients, although biomass and occupational exposures are important globally.
• Cardiovascular disease commonly coexists and contributes to dyspnea, admission, and mortality.

Investigations

When to Start Antibiotics

Pharmacology

Prognosis / Complications

• Most mild or moderate exacerbations improve over days with bronchodilators and corticosteroids.
• Acute hypercapnic respiratory failure, pneumonia, severe baseline COPD, frailty, and cardiovascular comorbidity worsen prognosis.
• An exacerbation requiring hospitalization predicts increased risk of death and recurrent admission during the following year.
• Successful NIV can avoid invasive ventilation and its complications in selected patients.
• Smoking cessation, appropriate maintenance inhalers, vaccination, and pulmonary rehabilitation reduce future risk.

Patient Education / Counseling

• Review inhaler technique directly rather than assuming the patient is using devices correctly.
• Provide a clear short-term plan for steroid and antibiotic completion and a separate long-term maintenance inhaler plan.
• Explain oxygen targets and home oxygen instructions if prescribed; patients should not adjust flow indiscriminately without guidance.
• Smoking cessation treatment should include medication and counseling when the patient is willing.
• Encourage influenza, COVID-19, pneumococcal, and other indicated respiratory vaccinations according to age and risk.
• Return precautions include worsening dyspnea, confusion, cyanosis, chest pain, inability to speak or walk because of breathlessness, or failure of rescue inhalers.

Notes

GOLD 2026 continues to emphasize differential diagnosis because heart failure, pulmonary embolism, pneumonia, and pneumothorax are common in COPD and can be missed when clinicians anchor on wheezing.

NIV is not merely a comfort intervention. In appropriate acute hypercapnic COPD respiratory failure it is a disease-modifying therapy that reduces intubation and mortality when applied early and monitored carefully.

References

1. GOLD 2026 Report and Pocket Guide — Link